CURE staff

A phase 3 trial update for GLSI-100 shows a recurrence rate of less than 1% per year in patients with HER2-positive breast cancer after immunization.

Studies show Signatera ctDNA testing may predict recurrence and guide treatment decisions in anal and rectal cancers.

The CAPTAIN trial shows MRI-guided TULSA preserved erectile and urinary function versus surgery in localized prostate cancer.

Learn about male breast cancer, including common symptoms, diagnostic tests and how hormone therapy or surgery is used to treat this rare disease.

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable with chemotherapy and radiation, with additional therapies available if the disease returns.

A study of 922 patients shows the Aida test predicts 10-year recurrence risk and helps guide radiation decisions for invasive breast cancer.

Preliminary INVINCIBLE-4 study data shows INT230-6 plus standard care may increase pathological complete response rates and improve patient safety.

Black Medicare patients with early-stage NSCLC continue to get surgery and radiation at lower rates than White patients, showing persistent treatment gaps.

Phase 2 interim data show NDV-01 produced high response rates and encouraging safety in patients with non–muscle-invasive bladder cancer.

The phase 3 persevERA study of giredestrant plus Ibrance missed its PFS goal, though positive data from other trials supports the drug.

FDA declined approval of retifanlimab for metastatic non–small cell lung cancer due to manufacturing issues at a third-party facility, not safety concerns.

The SUCCESSOR-2 study shows MeziKd improves progression-free survival for relapsed multiple myeloma patients previously treated with anti-CD38 drugs.

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

The FDA has received a new application for Anktiva plus BCG to treat BCG-unresponsive non–muscle invasive bladder cancer with papillary tumors.

FDA grants priority review to Enhertu for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after prior therapy, based on trial results showing longer disease control.

Phase 2 COMPASSION-03 data showed cadonilimab produced durable survival in patients with recurrent or metastatic cervical cancer after platinum chemotherapy.

Namodenoson was well tolerated in a phase 2a study of advanced pancreatic cancer, with one-third of patients alive at data cutoff.

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is expected late 2026.

Keytruda plus paclitaxel improved overall survival by 18% in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

Keytruda/Welireg and Welireg/Lenvima combinations show improved survival and disease control in kidney cancer, according to new data from ASCO GU.

Day two of ASCO GU highlighted innovative therapies and the need for better quality-of-life reporting in genitourinary cancer trials.

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a Phase 3 clinical trial.

The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 neutropenia and septic shock.

Five-year follow-up of cryoablation for small kidney tumors shows high recurrence-free rates and a minimally invasive option for select patients.

FDA granted fast track designation to AKY-1189 for adults with metastatic urothelial cancer after systemic therapy, aiming to speed development of the investigational drug.

The FDA granted fast track status to ART6043 plus Lynparza for patients with gBRCA-mutated HER2-negative breast cancer to accelerate drug development.

The FDA cleared an IND for FG001, allowing a U.S. trial in high-grade glioma, with first patient enrollment expected in second quarter of 2026.

Genentech announces FDA acceptance of giredestrant plus Afinitor for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer treatment.